MetaCap

MeiraGTx (MGTX) vs Odyssey Therapeutics (ODTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Odyssey Therapeutics is the larger company by market cap ($815.2 million vs $779.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MGTX-18.74%ODTX+3.29%
+80%+28%-23%
May 8, 20261 yearNov 20, 2026
MGTX-18.74%ODTX+3.29%
+80%+28%-23%
May 4, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MGTX versus ODTX key metrics
MetricMGTXODTX
Share price$7.98$16.96
Market cap$779.89M$815.23M
1-day change-1.97%-7.52%
YTD return+0.38%—
1-year return+6.97%—
5-year return-55.54%—
P/E ratio (TTM)9.17—
EPS (TTM)$0.87$-6.33
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$81.39M—
Revenue growth (YoY)+144.57%—
Net income (latest FY)$-114.20M—
Operating margin-130.20%—
Net margin-140.31%—
52-week high$15.35$29.05
52-week low$6.62$15.10
Distance from 52-week high-48.01%-41.62%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+247.74%+104.42%
Average volume837.25K329.31K
Shares outstanding97.73M48.07M
Employees386100
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About MeiraGTx

MGTX stock →

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 386 employees

About Odyssey Therapeutics

ODTX stock →

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor–associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 100 employees

MGTX vs ODTX FAQ

Which is bigger, MeiraGTx or Odyssey Therapeutics?

Odyssey Therapeutics (ODTX) is larger, with a market capitalization of $815.23M compared with $779.89M for MeiraGTx (MGTX).

Are MeiraGTx and Odyssey Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons